Helseøkonomisk analyse av bevacizumab+paclitaxel sammenlignet med paclitaxel alene som førstelinjebehandling ved metastatisk brystkreft

Hdl Handle:
Helseøkonomisk analyse av bevacizumab+paclitaxel sammenlignet med paclitaxel alene som førstelinjebehandling ved metastatisk brystkreft
Movik, Espen; Hamidi, Vida; Norderhaug, Inger Natvig; Klemp Gjertsen, Marianne
Rapport fra Kunnskapssenteret 5/2009
Additional Links:

Full metadata record

DC FieldValue Language
dc.contributor.authorMovik, Espen-
dc.contributor.authorHamidi, Vida-
dc.contributor.authorNorderhaug, Inger Natvig-
dc.contributor.authorKlemp Gjertsen, Marianne-
dc.identifier.citationRapport fra Kunnskapssenteret 5/2009en
dc.description.abstractBACKGROUND The Norwegian Knowledge Centre for the Health Services has been commissioned by Norwegian Directorate of Health’s Cancer Programme to make an assessment of the cost per progression-free year gained associated with the use of bevacizumab in combination with paclitaxel versus paclitaxel alone, as first line treatment for metastatic breast cancer. The result is likely to have bearings on a possible revision of the treatment guidelines for breast cancer in Norway. METHODS We developed a health economic model of the Markov type in which we compared data from a clinical study, Miller et al. 2007, with Norwegian cost data associated with the treatment alternatives. RESULTS Mean progression-free time in the group treated with bevacizumab+paclitaxel was 1 1.2 years whereas it was 0.73 years in the comparator group. This resulted in an incremental effect of 0,47 progression-free years. With regard to quality of life, the incremental effect was 0.2 QALYs. We estimated the incremental costs associated with use of bevacizumab+paclitaxel from a health service perspective to be NOK 765 000, which translates into a cost per progression-free life year gained of NOK 1.6 million and a cost per QALY gained of NOK 3.8 million. The estimate from the societal perspective, where tax, value-added tax and social security payments were deducted, was approx. NOK 1.3 million per progression-free life-year and NOK 3 million per QALY gained. CONCLUSION The cost per progression-free year gained is relatively high, and the cost per QALY gained is higher than cost-effective thresholds which have been proposed in Norway.en
dc.publisherNorwegian Knowledge Centre for the Health Servicesen
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Klinisk farmakologi: 739en
dc.subjectVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsfarmasi: 812en
dc.subject.meshBreast Neoplasmsen
dc.subject.meshNeoplasm Metastasisen
dc.subject.meshDrug Costsen
dc.subject.meshCost-Benefit Analysisen
dc.subject.meshHealth Care Costsen
dc.subject.meshAngiogenesis Inhibitorsen
dc.titleHelseøkonomisk analyse av bevacizumab+paclitaxel sammenlignet med paclitaxel alene som førstelinjebehandling ved metastatisk brystkreftno
dc.title.alternativeHealth economic analysis of bevacizumab+paclitaxel versus paclitaxel alone as first-line treatment for metastatic breast canceren
dc.typepeer revieweden
dc.contributor.departmentNasjonalt kunnskapssenter for helsetjenestenen
All Items in HeRA are protected by copyright, with all rights reserved, unless otherwise indicated.